Home/Solid Biosciences/Shuli Kulak, M.D.

SK

Shuli Kulak, M.D.

Head of Corporate Strategy and Business Development

Solid Biosciences

Therapeutic Areas

Neuromuscular Diseases Cardiac Diseases

Solid Biosciences Pipeline

Drug	Indication	Phase
SGT-003	Duchenne Muscular Dystrophy (Duchenne)	Phase I/II
SGT-212	Friedreich’s ataxia (FA)	Phase I/II
SGT-501	Catecholaminergic polymorphic ventricular tachycardia (CPVT)	Phase I/II
SGT-601	TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases	Preclinical

Leadership Team at Solid Biosciences

President and CEO

Chief Financial Officer

Jessie Hanrahan, Ph.D.

Chief Regulatory & Preclinical Operations Officer

Chief Operating Officer

Dr. Gabriel Brooks, M.D.

Chief Medical Officer

Chief Technology Officer

View full Solid Biosciences profile